

CHAD THERAPEUTICS INC

Form 10-Q

August 14, 2006

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q**

**Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934
For Quarterly Period Ended: June 30, 2006**

Or

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number: 1-12214
CHAD THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)**

California
(State of other jurisdiction of
incorporation or organization)

95-3792700
(I.R.S. Employer
Identification No.)

21622 Plummer Street, Chatsworth, CA

91311

(Address of principal executive offices)

(Zip Code)

(818) 882-0883

(Registrant's telephone number, including area code)

(Former Address)

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No
As of June 30, 2006, the registrant had 10,169,000 shares of its common stock outstanding.

TABLE OF CONTENTS

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risks

Item 4. Controls and Procedures

Part II

Item 1. Legal Proceedings

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Item 6. Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 31.1

EXHIBIT 31.2

EXHIBIT 32

EX-99.1

Table of Contents

CHAD THERAPEUTICS, INC.
Condensed Balance Sheets
June 30, 2006 and March 31, 2006
(Unaudited)

	June 30, 2006	March 31, 2006
ASSETS		
Current assets:		
Cash	\$ 1,704,000	\$ 935,000
Accounts receivable, less allowance for doubtful accounts of \$43,000 at June 30, 2006, and \$52,000 at March 31, 2006	3,184,000	3,220,000
Income taxes refundable	290,000	383,000
Inventories (Note 5)	6,257,000	6,381,000
Prepaid expenses and other assets	159,000	178,000
Deferred income taxes	662,000	666,000
Total current assets	12,256,000	11,763,000
Property and equipment, at cost	6,150,000	6,101,000
Less accumulated depreciation	5,249,000	5,151,000
Net property and equipment	901,000	950,000
Intangible assets, net	1,038,000	972,000
Deferred income taxes	613,000	600,000
Other assets	55,000	71,000
Total assets	\$ 14,863,000	\$ 14,356,000
 LIABILITIES AND SHAREHOLDERS EQUITY		
Current liabilities:		
Accounts payable	\$ 1,009,000	\$ 522,000
Accrued expenses	1,523,000	1,435,000
Total current liabilities	2,532,000	1,957,000
Other long-term liabilities	2,000	4,000
Total liabilities	2,534,000	1,961,000
Shareholders' equity:		
Common shares, \$.01 par value, authorized 40,000,000 shares; 10,169,000 and 10,158,000 shares issued and outstanding	13,463,000	13,413,000
Accumulated deficit	(1,134,000)	(1,018,000)

Edgar Filing: CHAD THERAPEUTICS INC - Form 10-Q

Total shareholders' equity	12,329,000	12,395,000
Total liabilities and shareholders' equity	\$ 14,863,000	\$ 14,356,000

See accompanying notes to condensed financial statements.

Table of Contents

CHAD THERAPEUTICS, INC.
Condensed Statements of Operations
For the three months ended June 30, 2006 and 2005
(Unaudited)

	Three Months Ended June 30,	
	2006	2005
Net sales	\$ 5,476,000	\$ 5,895,000
Cost of sales	3,662,000	3,794,000
Gross profit	1,814,000	2,101,000
Costs and expenses:		
Selling, general, and administrative	1,702,000	1,844,000
Research and development	335,000	332,000
Total costs and expenses	2,037,000	2,176,000
Operating loss	(223,000)	(75,000)
Other income	23,000	6,000
Loss before income taxes	(200,000)	(69,000)
Income tax benefit	(84,000)	(27,000)
Net loss	\$ (116,000)	\$ (42,000)
Basic earnings (loss) per share	\$ (0.01)	\$ 0.00
Diluted earnings (loss) per share	\$ (0.01)	\$ 0.00
Weighted shares outstanding:		
Basic	10,169,000	10,134,000
Diluted	10,169,000	10,134,000

See accompanying notes to condensed financial statements.

Table of Contents

CHAD THERAPEUTICS, INC.
 Condensed Statement of Shareholders' Equity
 For the three months ended June 30, 2006
 (Unaudited)

	Common Shares		Accumulated Deficit
	Shares	Amount	
Balance as of March 31, 2006	10,158,000	\$ 13,413,000	\$ (1,018,000)
Stock-based compensation		10,000	
Restricted stock	11,000	40,000	
Net loss			(116,000)
Balance at June 30, 2006	10,169,000	13,463,000	\$ (1,134,000)

See accompanying notes to condensed financial statements.

Table of Contents

CHAD THERAPEUTICS, INC.
Condensed Statement of Cash Flows
For the three months ended June 30, 2006 and 2005
(Unaudited)

	Three Months Ended June 30,	
	2006	2005
Cash flows from operating activities:		
Net loss	\$ (116,000)	\$ (42,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Depreciation and amortization of property and equipment	98,000	108,000
Amortization of intangibles	11,000	10,000
Provision for losses on receivables		3,000
Decrease (increase) in deferred income taxes	(9,000)	(27,000)
Stock-based compensation	20,000	
Changes in assets and liabilities:		
Decrease (increase) in accounts receivable	36,000	441,000
Decrease (increase) in inventories	124,000	365,000
Decrease (increase) in income taxes refundable	93,000	119,000
Decrease (increase) in prepaid expenses and other assets	35,000	3,000
Increase (decrease) in accounts payable	487,000	(421,000)
Increase (decrease) in accrued expenses	118,000	51,000
Increase (decrease) in income taxes payable		(188,000)
Net cash provided by operating activities	897,000	422,000
Cash flows from investing activities:		
Additions to intangible assets	(77,000)	(45,000)
Capital expenditures	(49,000)	(83,000)
Net cash used in investing activities	(126,000)	(128,000)
Cash flows from financing activities:		
Other long-term liabilities	(2,000)	
Net cash used in financing activities	(2,000)	
Net increase in cash	769,000	294,000
Cash beginning of period	935,000	177,000
Cash end of period	\$ 1,704,000	\$ 471,000

See accompanying notes to condensed financial statements.

Table of Contents

CHAD THERAPEUTICS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)

1. Interim Reporting

CHAD Therapeutics, Inc. (the Company) is in the business of developing, producing, and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases.

In the opinion of management, all adjustments necessary, which are of a normal and recurring nature, for a fair presentation of the results for the interim periods presented, have been made. The results for the three-month period ended June 30, 2006, are not necessarily indicative of the results expected for the year ended March 31, 2007. The interim statements are condensed and do not include some of the information necessary for a more complete understanding of the financial data. Accordingly, your attention is directed to the footnote disclosures found in the March 31, 2006, Annual Report and particularly to Note 1 which includes a summary of significant accounting policies.

2. Revenue Recognition

The Company recognizes revenue when title and risk of loss transfers to the customer and the earnings process is complete. Under a sales-type lease agreement, revenue is recognized at the time of shipment with interest income recognized over the life of the lease. The Company records all shipping fees billed to customers as revenue, and related costs as costs of good sold, when incurred.

3. Major Customers

	Three Months Ended June 30,	
	2006	2005
Customer A**	36.6%	36.5%
Customer B	12.8%	*

* Indicates sales less than 10% of the Company's net sales

** Indicates national chain customer

The Company's customers are affected by Medicare reimbursement policy as approximately 80% of home oxygen patients are covered by Medicare and other government programs.

4. Concentration of Credit Risk

At times the Company maintains balances of cash that exceed \$100,000 per account, the maximum insured by the Federal Deposit Insurance Corporation. The Company's right to the cash is subject to the risk that the financial institution will not pay when cash is requested. The potential loss is the amount in any one account over \$100,000. At June 30, 2006, the amount at risk was approximately \$1,604,000.

Table of Contents

The significant outstanding accounts receivable balances in 2006 were as follows:

	June 30	March 31
Customer A**	28.1%	25.4%
Customer B	21.8%	21.6%

** Indicates national chain customer.

5. Inventories

Inventories in 2006 are summarized as follows:

	June 30	March 31
Finished goods	\$ 1,694,000	\$ 1,706,000
Work-in-process	1,626,000	1,234,000
Raw materials	2,937,000	3,441,000
	\$ 6,257,000	\$ 6,381,000

6. Line of Credit

In December 2005, the Company entered into a \$1 million revolving line of credit agreement that expires in December 2006. Advances under the line of credit bear interest at the bank's prime rate (8.25% at June 30, 2006) and are secured by inventories and accounts receivable. Under the terms of the credit agreement, the Company is required to maintain a specific working capital, net worth, profitability levels, and other specific ratios. In addition, the agreement prohibits the payment of cash dividends and contains certain restrictions on the Company's ability to borrow money or purchase assets or interests in other entities without prior written consent of the bank. At June 30, 2006, the Company was not in compliance with certain of the covenants related to profitability and is currently renegotiating changes to the line of credit. There were no borrowings under the line of credit at June 30, 2006.

7. Leasing Arrangements

In the second quarter of fiscal year 2006, the Company entered into a capital lease agreement for certain plant equipment totaling \$14,000, with annual lease payments of \$7,000, a fixed interest rate of 7% and a purchase option at lease end in August 2007. The current portion of \$7,000 and the long-term portion of \$2,000 is included in accounts payable and other long-term liabilities, respectively. Amortization of plant equipment under capital leases is included in depreciation expense.

Table of Contents**8. Earnings (Loss) Per Common Share**

Following is a reconciliation of the numerators and denominators used in the calculation of basic and diluted earnings (loss) per common share:

	Three Months Ended June 30,	
	2006	2005
Basic earnings (loss) per share:		
Numerator-net earnings (loss)	\$ (116,000)	\$ (42,000)
Denominator-weighted average common shares outstanding	10,169,000	10,134,000
Basic earnings (loss) per share	\$ (0.01)	\$ 0.00
Diluted earnings (loss) per share:		
Numerator-net earnings (loss)	\$ (116,000)	\$ (42,000)
Denominator-weighted average common shares outstanding	10,169,000	10,134,000
Diluted effect of common stock options		
	10,169,000	10,134,000
Diluted earnings (loss) per share	\$ (0.01)	\$ 0.00

Options to purchase 941,000 shares of common stock at prices ranging from \$0.50 to \$11.50 per share and 975,000 shares of common stock at prices ranging from \$0.50 to \$12.54 were not included in the computation of diluted earnings per share for the three month periods ended June 30, 2006 and 2005, respectively, because their effect would have been anti-dilutive.

9. Income Tax Expense

Based on management's earnings projections for the fiscal year ended 2007, the Company has forecasted an effective tax rate of 42 percent. The Company has California net operating loss carryforwards of \$2,364,000 of which \$606,000 expires in 2007 and the remaining balance expires in 2013.

Table of Contents**10. Geographic Information**

The Company has one reportable operating segment. Geographic information regarding the Company's net sales is as follows:

	Three Months Ended June 30,	
	2006	2005
United States	\$ 4,354,000	\$ 5,121,000
Canada	54,000	56,000
Japan	126,000	188,000
Europe	854,000	466,000
All other countries	88,000	64,000
	\$ 5,476,000	\$ 5,895,000

All long-lived assets are located in the United States.

Sales of OXYMATIC®, LOTUS and CYPRESS OXYPneumatic® conservers and SAGE Therapeutic devices accounted for 70% of the Company's sales for the three-month periods ended June 30, 2006 and 2005.

11. Stock Option Plan

On April 1, 2006, the Company adopted Statement of Financial Accounting Standards 123R, Share-Based Payment, which revised SFAS 123, Accounting for Stock-Based Compensation. The Company adopted FAS 123R using the modified prospective transition method. Previously, the Company had followed APB 25, accounting for employee stock options at intrinsic value. Accordingly, during the three-month period ended June 30, 2006, the Company recorded stock-based compensation expense for awards granted prior to, but not yet vested, as of April 1, 2006, as if the fair value method required for pro forma disclosure under FAS 123 were in effect for expense recognition purposes, adjusted for estimated forfeitures. For stock-based awards granted after April 1, 2006, the Company will recognize compensation expense based on the estimated grant date fair value method using the Black-Scholes valuation model. For these awards, the Company will recognize compensation expense using a straight-line method. As FAS 123R requires that stock based compensation expense be based on awards that are ultimately expected to vest, stock-based compensation for the three-month period ended June 30, 2006 has been reduced for estimated forfeitures. For the three-month period ended June 30, 2006 stock-based compensation expense of \$10,000 was recorded to selling, general, and administrative expenses. Due to the prospective adoption of SFAS No. 123R, results for prior period have not been restated.

The Company has an equity incentive plan (the Plan) for key employees as defined under Section 422(A) of the Internal Revenue Code. The Plan provides that 750,000 common shares be reserved for issuance under the Plan, which expires on September 8, 2014, of which approximately 705,000 are available were available for future grant at June 30, 2006. In addition, the Plan provides that non-qualified options can be granted to directors and independent contractors of the Company. Stock options are granted with an exercise price equal to the market value of a share of the Company's

Table of Contents

stock on the date of the grant. Historically, grants to non-employee directors have vested over two years while the majority of grants to employees have vested over two to five years of continuous service. In fiscal year 2006, 40,000 options were issued with vesting periods less than one year. All options granted to date have ten-year contractual terms from the date of the grant.

The fair value of each stock option award is estimated on the date of the grant using the Black-Scholes option valuation model. Expected volatility is based on the historical volatility of the Company's stock. No expected dividend yield is used since the Company has not historically declared or paid dividends and no dividends are expected in the foreseeable future. The risk-free interest rate is based on the U.S. treasury yield curve on the grant date for the expected term of the option. The Company did not grant any stock options during the three months ended June 30, 2006. The following weighted-average assumptions were used in calculating the fair value of stock options granted during the three months ended June 30, 2005 using the Black-Scholes option valuation model:

Expected life (in years)	8.0
Expected volatility factor	79.0%
Risk free interest rate	4.3%
Dividend yield	0.0
Forfeiture rate	4.0%

A summary of stock option activity as of and for the quarter ended June 30, 2006 is presented below:

	Shares	Exercise Price Per Share	Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at March 31, 2006	945,000	\$ 2.22		
Granted				
Exercised				
Forfeited or expired	4,000	3.41		
Outstanding at June 30, 2006	941,000	\$ 2.21	4.8	\$
As of June 30, 2006:				
Exercisable	899,000	\$ 2.22	4.8	\$
Vested and expected to vest	925,000	\$ 2.25	4.8	\$

No options were granted or exercised during the first quarter of fiscal year 2007 or 2006.

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock at June 30, 2006 for the options that were in-the-money at June 30, 2006. As of June 30, 2006, there was approximately \$52,000 of unrecognized compensation cost related to unvested stock-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 13 months.

Table of Contents

Prior to the adoption of FAS 123R, the Company provided the disclosures required under FAS 123, as amended by FAS No. 148, Accounting for Stock-Based Compensation Transitions and Disclosures. Employee stock-based compensation expense recognized under FAS 123R was not reflected in our results of operations for the three-month period ended June 30, 2005 as all options were granted with an exercise price equal to the market value of the underlying common stock on the date of the grant. The pro forma information for the three months ended June 30, 2005 is as follows:

	Three Months Ended June 30, 2005
Net loss, as reported	\$ (42,000)
Deduct: Total stock-based employee compensation expense determined under fair value-based method for all awards, net of related tax effects	21,000
Pro forma net loss	\$ (63,000)
Earnings (loss) per share:	
Basic as reported	\$ 0.00
Basic proforma	(0.01)
Diluted as reported	0.00
Diluted proforma	\$ (0.01)

12. Reclassifications

Certain reclassifications have been made to the fiscal year 2006 financial data to conform with the 2007 presentation. The Company added provisions for losses on receivables as an adjustment to reconcile net earnings (loss) to net cash provided by operating activities to its condensed statements of cash flows.

13. Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses, and the disclosure of contingent assets and liabilities at the date of the financial statements. Actual results may differ from those estimates.

14. Accounting Standards

In November 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 151 (Inventory Costs), an amendment of ARB No. 43, Chapter 4. The statement clarifies accounting for abnormal amounts of the idle facility expense, freight, handling costs, and spoilage and requires those items to be expensed when incurred. SFAS 151 is applicable to inventory costs incurred during fiscal years beginning after June 15, 2005. The Company adopted SFAS No. 151 on April 1, 2006, and the Company did not incur a significant impact to its financial statements.

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 123R (Share-Based Payment). SFAS 123R requires the Company to recognize compensation expense based on the fair

Table of Contents

value of equity instruments awarded to employees. The Company adopted SFAS 123R on April 1, 2006, and the Company did not incur a significant impact to its financial statements.

In June 2006, the Financial Accounting Standards Board ratified EITF Issue No. 06-3, How Taxes Collected from Customers and Remitted to Governmental Authorities Should be Presented in the Income Statement. The EITF provides guidance on the proper presentation of tax assessed by a governmental authority that is directly imposed on a revenue-producing transaction between a seller and a customer and requires disclosure of the Company's accounting policy decision. The consensus becomes effective for periods beginning after December 15, 2006. The Company is evaluating the impact of this interpretation and does not anticipate a significant impact to its financial statements upon implementation.

In June 2006, the Financial Accounting Standards Board issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes. Interpretation No. 48 prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. This Interpretation is effective for fiscal years beginning after December 15, 2006. The Company is evaluating the impact of this interpretation and does not anticipate a significant impact to its financial statements upon implementation.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Statement

Certain statements in this report, including statements regarding our strategy, financial performance and revenue sources, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and are subject to the safe harbors created by those sections. These forward-looking statements are based on our current expectations, estimates and projections about our industry, management's beliefs, and certain assumptions made by us. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. The section entitled "Outlook Issues and Risk" set forth in this Form 10-Q and similar discussions in filings with the Securities and Exchange Commission made from time to time, including other quarterly reports on Form 10-Q, our Annual Reports on Form 10-K, and in our other SEC filings, discuss some of the important risk factors that may affect our business, results of operations and financial condition.

The following discussion should be read in conjunction with our condensed financial statements and notes thereto.

Overview

CHAD Therapeutics, Inc. (the "Company") develops, assembles and markets medical devices that furnish supplementary oxygen to home health care patients. The Company was a pioneer in developing oxygen conserving devices that enhance the quality of life for patients by increasing their mobility and, at the same time, lower operating costs by achieving significant savings in the amount of oxygen actually required to properly oxygenate patients. The market for oxygen conserving devices has been, and continues to be, significantly affected by increased competition, consolidation among home oxygen dealers, and revisions (and proposed revisions) in governmental reimbursement policies. All of these factors, as described more fully below, have contributed to a more competitive market for the Company's products.

The current procedures for reimbursement by Medicare for home oxygen services provide a prospective flat fee monthly payment based solely on the patient's prescribed oxygen requirement. Beginning January 1, 2006, the reimbursement procedures have been modified to provide that title for the equipment being used by a patient transfers to the patient after 36 months. Under this system, inexpensive concentrators have grown in popularity because of low cost and less frequent servicing requirements. At the same time, oxygen conserving devices, such as the Company's products, have also grown in popularity due to their ability to extend the life of oxygen supplies and reduce service calls by dealers, thereby providing improved mobility for the patient and cost savings for dealers. However, the uncertainties created by the new reimbursement procedures have

Table of Contents

adversely affected the market for our products by causing many home health care dealers to delay product purchases as they seek to assess the impact of the new procedures.

In addition, other changes in the health care delivery system, including the increase in the acceptance and utilization of managed care, have stimulated a significant consolidation among home care providers. Major national and regional home medical equipment chains have continued to expand their distribution networks through the acquisition of independent dealers in strategic areas. Margins on sales to national chains are generally lower due to quantity pricing and management anticipates continued downward pressure on its average selling price. Four major national chains accounted for approximately 43% and 44% of the Company's net sales for the three-month periods ended June 30, 2006 and 2005, respectively while one chain accounted for 37% of net sales for the three-month periods ended June 30, 2006 and 2005. One international customer accounted for 13% and 7% of net sales during the three-month periods ended June 30, 2006 and 2005, respectively. This increased dependence on a limited number of large customers may result in greater volatility and unpredictability of future operating results as changes in the purchasing decisions by one or more major customers can have a material effect upon our financial statements.

The Company believes that price competition and continuing industry consolidation will continue to affect the marketplace for the foreseeable future. To address the competitive nature of the oxygen conserver marketplace, the Company has developed and introduced a number of new products in this area in recent years. The first of these, the OXYMATIC® 401 conserver, received 510(k) clearance from the Food and Drug Administration in June 2000, and shipments of the new product began in July 2000. The second, the OXYMATIC 411 conserver, was cleared in December 2000 and shipments began in January 2001. The third, the OXYMATIC 401A and 411A conservers, received clearance in March 2001 with shipments beginning that month. The SEQUOIA OXYMATIC 300 series conservers began shipping in December 2001, and the Company began shipment of the CYPRESS OXYPneumatic conserver in July 2002. The Company received clearance from the FDA to market its newest oxygen conserving device, the LOTUS Electronic Oxygen Conserver, in October 2004 and began shipment of the device in November 2005. The LOTUS Electronic Oxygen Conserver weighs less than one (1) pound and will be offered with or without a breath-sensing alarm. It also offers additional liter flow settings and an extended battery life of up to four months of normal usage on two AA-size batteries. Management believes the features and improvements in these products have enabled the Company to regain some of the market share lost in the conserver market prior to 2001 and reestablish the Company as a leader in the conserver market.

In May of 2004, the Company received clearance from the FDA to market its SAGE Oxygen Therapeutic Device. The SAGE device is the first in a planned family of oxygen therapeutic devices that use the Company's proprietary technologies to sense a patient's movements and automatically adjust the rate of oxygen delivery to reduce the risk of desaturation as activity increases. This device combines the industry's first, truly dynamic delivery technology with the proven oxygen sensor technology in the OXYMATIC 400 series conservers. As a result, the SAGE Oxygen Therapeutic Device addresses the common problem of oxygen desaturation, which causes a patient to feel weak and out of breath when activity increases, while it still improves patient ambulatory capability. This device underscores the Company's dedication to providing home care

Table of Contents

suppliers and their patients with the widest range of home oxygen choices to suit individual needs, preferences and disease conditions. The Company began selling the SAGE nationwide in October 2004. No estimate can currently be made regarding the level of success the Company may achieve with this line of products or when the additional therapeutic devices that are now in development, and which are based on this advanced new platform, may be introduced to the market.

In 1998, the Company introduced the TOTAL O2[®] Delivery System, which provides stationary oxygen for patients at home, portable oxygen, including an oxygen conserving device for ambulatory use, and a safe and efficient mechanism for filling portable oxygen cylinders in the home. This provides home care dealers with a means to reduce their monthly cost of servicing patients while at the same time providing a higher quality of service by maximizing ambulatory capability. The Company received clearance in November 1997 from the Food and Drug Administration to sell this product. Initial sales of the TOTAL O2 system were adversely affected by several factors, including the overall home oxygen market climate as well as home care providers' reluctance to invest in the higher cost of the TOTAL O2 Delivery System to achieve the lower monthly operating costs. Recent changes in home oxygen reimbursement appear to be causing home care providers to examine their operating costs more carefully and this is improving the marketing climate for the TOTAL O2 system.

The Company's growth strategy for the future includes the following:

Development of additional oxygen conserver models, such as the LOTUS Electronic Oxygen Conserver with a view to diversifying the product line in order to offer customers a range of oxygen conservation choices;

An effort to expand the Company's product lines and improve existing products through the investment in and development of new technologies, such as proprietary sensor technology and control software licensed in January of 2003 and the introduction of the SAGE Oxygen Therapeutic Device in May 2004. These new technologies should provide the Company with an opportunity to expand its oxygen delivery product lines and potentially enter the high-growth sleep disorder market; and

A continued promotional and educational campaign with respect to the benefits of the TOTAL O2 system.

While management believes the current growth strategy should enhance the Company's competitive position and future operating performance, continuing price pressure on our conservers and concerns about reimbursement change have depressed operating results for the first three months of fiscal 2007. In addition, the Company's increased dependence on a limited number of large customers has increased the volatility of our operating results. Management of the Company will continually monitor these trends and will attempt to remain flexible in order to adjust to possible future changes in the market for respiratory care devices. For information that may affect the outcome of forward-looking statements in this Overview regarding the Company's business strategy and its introduction of new products, see Outlook: Issues and Risks - New Products, Consolidation of Home Care Industry, Competition, Rapid Technological Change, and

Table of Contents

Potential Changes in the Administration of Health Care, beginning on page 17 of the Company's 2005 Annual Report. Results of Operations

Net sales for the three-month periods ended June 30, 2006 and 2005, decreased by \$419,000 (7.1%) and \$204,000 (3.3%), respectively, as compared to the same periods in the prior year. The primary reason for the decrease in sales for the three-month periods ended June 30, 2006 was price reductions on conservers; however the decrease in sales for the three months ended June 30, 2005 was also impacted by reduced sales to a large customer. Unit sales of conservers and therapeutic devices for the three months ended June 30, 2006 increased 3.9%, from the prior year, while unit sales for the three-month period ended June 30, 2005 decreased 4.1%. However, revenues from conserver and therapeutic device sales decreased by 7.5% and 13.9% for the three-month periods ended June 30, 2006 and 2005, respectively. As noted above, management expects continued downward pressure on its average selling price. In addition, future operating results may be increasingly dependent upon purchase decisions of a limited number of large customers.

Revenues from TOTAL O2 sales decreased 16.6% for the three-month period ended June 30, 2006 as compared to the same period in the prior year. The Company believes that the January 2, 2006 modification of reimbursement procedures that provides for title of equipment being used by a patient to transfer to the patient after 36 months is impacting the Company's sales overall and in particular sales of the TOTAL O2. Revenues from TOTAL O2 sales increased 16.7% for the three-month period ended June 30, 2005 as compared to the same period in the prior year due to sales to a large customer and continued acceptance of this product in the marketplace.

Sales to foreign distributors represented 20.5% and 13.3% of net sales for the three-month periods ended June 30, 2006 and 2005, respectively, representing a 42.8% and a 161.8% increase over the respective previous years. This increase was driven by higher conserver sales and management expects this trend to continue for the balance of the current fiscal year. Management believes there may be substantial growth opportunities for the Company's products in a number of foreign markets and we currently expect an increase in sales to foreign distributors during the upcoming twelve months. However, quarter-to-quarter sales may fluctuate depending on the timing of shipments. All foreign sales are denominated in US dollars.

Cost of sales as a percent of net sales increased from 64.4% to 66.9% and from 60.3% to 64.4% for the three-month periods ended June 30, 2006 and 2005, respectively, as compared to the same periods in the prior year. For the three-month period ended June 30, 2006, the increase in cost of sales as a percentage of net sales was a result of downward price pressures in the marketplace, as well as the decrease in sales without a corresponding decrease in fixed costs. For the period ended June 30, 2005, the increase was a result of downward price pressures in the marketplace, increased sales to certain chains, and a change in the product mix, as the TOTAL O2 system has a lower gross profit margin than conservers. We currently expect downward price pressure for the foreseeable future.

Table of Contents

Selling, general, and administrative expenditures decreased from 31.3% to 31.1% and increased from 28.5% to 31.3% as a percentage of net sales for the three-month periods ended June 30, 2006 and 2005, as compared to the same periods in the prior year. The Company's cost reduction efforts over the past two years have helped align staffing and operating expenses more closely with current sales expectations but were offset to some extent by growth in the Company's sales force. Research and development expenses increased by \$3,000 and decreased by \$78,000 for the three-month periods ended June 30, 2006 and 2005, respectively, as compared to the same periods in the prior year. Currently management expects research and development expenditures to total approximately \$1,500,000 in the fiscal year ending March 31, 2007, on projects to enhance and expand the Company's product line. During fiscal year 2006, the Company spent \$1,574,000 on research and development.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. At June 30, 2006, the Company's net deferred tax assets are partially offset by a valuation allowance. The Company will continue to assess the valuation allowance and to the extent it is determined that such allowance is no longer required, the tax benefit of the remaining net deferred tax assets will be recognized in the future. The Company has California net operating loss carryforwards of \$2,364,000 against which a partial allowance has been recorded.

Financial Condition

At June 30, 2006, the Company had cash totaling \$1,704,000 or 11.5% of total assets, as compared to \$935,000 (6.5% of total assets) at March 31, 2006. Net working capital decreased from \$9,806,000 at March 31, 2006 to \$9,724,000 at June 30, 2006. Net accounts receivable decreased \$36,000 during the three months ended June 30, 2006, due to the timing of payments from significant customers. Future increases or decreases in accounts receivable will generally coincide with sales volume fluctuations and the timing of shipments to foreign customers. During the same period, inventories decreased \$124,000. The Company attempts to maintain sufficient inventories to meet its customer needs as orders are received and new products are introduced. Thus, future inventory and related accounts payable levels will be impacted by the ability of the Company to maintain its safety stock levels. If safety stock levels drop to target amounts, then inventories in subsequent periods will increase more rapidly as inventory balances are replenished. The Company experienced a significant inventory build up in the latter part of fiscal 2005 to fill certain customer orders and anticipated customer orders of the SAGE device. Certain of these orders did not materialize or were deferred. In March 2006, the Company established a \$739,000 reserve against slow-moving inventories related to the build-up. The Company depends primarily upon its cash flow from operations to meet its capital requirements. Cash derived from operations will depend on the ability of the Company to maintain profitable operations and the timing of increases in receivables and inventories. Historically, the Company has financed its inventory requirements out of cash flow, and it has not sought to finance its accounts receivable. In December 2005, the Company entered into a \$1 million line of credit agreement. The line of credit was established in order to fund anticipated capital expenditures. As of June 30, 2006, there were no borrowings under the line of credit. Advances under the line of credit bear

Table of Contents

interest at the bank's prime rate (7.25% at December 31, 2005) and are secured by inventories and accounts receivable. Under the terms of the credit agreement, the Company is required to maintain a specific working capital, net worth, profitability levels, and other specific ratios. In addition, if advances were outstanding, the agreement would prohibit the payment of cash dividends and contains certain restrictions on the Company's ability to borrow money or purchase assets or interests in other entities without prior written consent of the bank. At June 30, 2006, the Company was not in compliance with certain of the covenants related to profitability and is currently negotiating changes to the line of credit agreement. The Company expects capital expenditures during the next twelve months to be approximately \$476,000 and anticipates that cash flow from operations will be adequate to fund the Company's planned capital expenditures.

The following table aggregates all of the Company's material contractual obligations as of June 30, 2006:

	Payments Due by Period				
	Total	Less than 1 Year	1 - 3 Years	3-5 Years	After 5 Years
Contractual					
Cash Obligations					
Operating lease obligations	\$ 888,000	\$ 435,000	\$ 453,000		
Minimum royalty obligations	\$ 2,937,000	\$ 523,000	\$ 1,590,000	\$ 757,000	\$ 67,000
Employee obligations	\$ 440,000	\$ 160,000	\$ 280,000		
Capital lease obligations	\$ 9,000	\$ 7,000	\$ 2,000		

Operating lease commitments consist primarily of a real property lease for the Company's corporate office, as well as minor equipment leases. Payments for these lease commitments are provided for by cash flows generated from operations. Please see Note 8 to the financial statements in the 2006 Annual Report.

Employee obligations consist of an employment agreement (the "Employment Agreement") with Thomas E. Jones Chairman of the Board of Directors. The Employment Agreement does not have a specific term and provides for a base salary of \$160,000 per year, which is subject to annual review of the Board of Directors. The Employment Agreement may be terminated at any time by the Company, with or without cause, and may be terminated by Mr. Jones upon 90 days' notice. If Mr. Jones resigns or is terminated for cause (as defined in the Employment Agreement), he is entitled to receive only his base salary and accrued vacation through the effective date of his resignation or termination. If Mr. Jones is terminated without cause, he is entitled to receive a severance benefit in accordance with the Company's Severance and Change of Control Plan, or if not applicable, a severance benefit equal to 200% of his salary and incentive bonus for the prior fiscal year. In estimating its contractual obligation, the Company has assumed that Mr. Jones will voluntarily retire at the end of the year he turns 65 and that no severance benefit will be payable. This date may not represent the actual date the Company's payment obligations under the Employment Agreement are extinguished.

Table of Contents

The Company does not have any outstanding debt and is not subject to any covenants or contractual restrictions limiting its operations with the exception of those required by its line of credit agreement indicated above. The Company has not adopted any programs that provide for post-employment retirement benefits; however, it has on occasion provided such benefits to individual employees. The Company does not have any off-balance sheet arrangements with any special purpose entities or any other parties, does not enter into any transactions in derivatives, and has no material transactions with any related parties.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates under different assumptions and conditions. Management believes that the following discussion addresses the accounting policies and estimates that are most important in the portrayal of the Company's financial condition and results.

Allowance for doubtful accounts – the Company provides a reserve against receivables for estimated losses that may result from our customers' inability to pay. The amount of the reserve is based on an analysis of known uncollectible accounts, aged receivables, historical losses, and credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this reserve. The likelihood of material losses is dependent on general economic conditions and numerous factors that affect individual accounts.

Inventories – the Company provides a reserve against inventories for excess and slow moving items. The amount of the reserve is based on an analysis of the inventory turnover for individual items in inventory. The likelihood of material write-downs is dependent on customer demand and competitor product offerings.

Intangible and long-lived assets – The Company assesses whether or not there has been an impairment of intangible and long-lived assets in evaluating the carrying value of these assets. Assets are considered impaired if the carrying value is not recoverable over the useful life of the asset. If an asset is considered impaired, the amount by which the carrying value exceeds the fair value of the asset is written off. The likelihood of a material change in the Company's reported results is dependent on each asset's ability to continue to generate income, loss of legal ownership or title to an asset, and the impact of significant negative industry or economic trends.

Deferred income taxes – the Company provides a valuation allowance to reduce deferred tax assets to the amount expected to be realized. The likelihood of a material change in the expected realization of these assets depends on the Company's ability to generate future taxable income.

Revenue recognition – The Company recognizes revenue when title and risk of loss transfers to the customer and the earnings process is complete. Under a sales-type lease

Table of Contents

agreement, revenue is recognized at the time of shipment with interest income recognized over the life of the lease. The Company records all shipping fees billed to customers as revenue, and related costs as costs of good sold, when incurred.

Outlook: Issues & Risks

The report contains forward-looking statements, which reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, which may cause actual operating results to differ materially from currently, anticipated results. Among the factors that could cause actual results to differ materially are the following:

Dependence Upon a Single Product Line

Although the Company currently markets a number of products, these products comprise a single product line for patients requiring supplementary oxygen. The Company's future performance is thus dependent upon developments affecting this segment of the health care market and the Company's ability to remain competitive within this market sector.

Consolidation of Home Care Industry Dependence on Key Customers Pressure on Selling Prices

The home health care industry is undergoing significant consolidation. As a result, the market for the Company's products is increasingly influenced by major national chains. Four major national chains accounted for 43% of the Company's net sales during the year ended March 31, 2006 and for the three months ended June 30, 2006. One major customer accounted for 36% of net sales for the year ended March 31, 2006, and 37% for the three months ended June 30, 2006. Future sales may be increasingly dependent upon a limited number of customers, which may reduce our average selling price due to quantity pricing and which may result in greater volatility and less predictability of the Company's operating results. Moreover, the loss of a major customer or a significant decline in orders from a major customer could have a material adverse effect upon the Company's revenues and profitability.

New Products

The Company's future growth in the near term will depend in significant part upon its ability to successfully introduce new products. In recent years, the Company has introduced the OXYMATIC 400 series, the SEQUOIA, CYPRESS OXYPneumatic, and LOTUS conservers, and the TOTAL O2 Delivery System and in May 2004 introduced the SAGE Oxygen Therapeutic Device. The Company is currently developing additional new products. The success of the Company's products will depend upon the health care community's perception of such products' capabilities, clinical efficacy, and benefit to patients as well as obtaining timely regulatory approval for new products. In addition, prospective sales will be impacted by the degree of acceptance achieved among home oxygen dealers and patients requiring supplementary oxygen. The Company's ability to continue to successfully develop, introduce, and promote new products cannot be determined at this time.

Table of Contents

Competition

The Company's success in the early 1990's has drawn competition to vie for a share of the home oxygen market. These new competitors include both small and very large companies. While the Company believes the quality of its products and its established reputation will continue to be a competitive advantage, some competitors have successfully introduced lower priced products that do not provide oxygen conserving capabilities comparable to the Company's products. Most of these competitors have greater capital resources than the Company. Some of the competitors benefit from being able to offer dealers a broad range of home health care products, while the Company's products are limited to supplementary oxygen devices. The Company expects the increased competition in the home oxygen market will continue to intensify with adverse effects on the prices the Company can charge for certain of its products.

Availability and Reliability of Third Party Component Products

The Company tests and packages its products in its own facility. Some of its other manufacturing processes are conducted by other firms. The Company expects to continue using outside firms for certain manufacturing processes for the foreseeable future and is thus dependent on the reliability and quality of parts supplied by these firms. From time to time, the Company has experienced problems with the reliability of components produced by third party suppliers. The Company's agreements with its suppliers are terminable at will or by notice. The Company believes that other suppliers would be available in the event of termination of these arrangements. No assurance can be given, however, that the company will not suffer a material disruption in the supply of parts required for its products.

Rapid Technological Change

The health care industry is characterized by rapid technological change. The Company's products may become obsolete as a result of new developments. The Company's ability to remain competitive will depend to a large extent upon its ability to anticipate and stay abreast of new technological developments related to oxygen therapy. The Company has limited internal research and development capabilities. Historically, the Company has contracted with outside parties to develop new products. Some of the Company's competitors have substantially greater funds and facilities to pursue research and development of new products and technologies for oxygen therapy.

Potential Changes in Administration of Health Care

A number of proposals to regulate, control or alter the method of financing health care costs have been discussed and certain such bills have been introduced in Congress and various state legislatures. Because of the uncertain state and widely varying terms of health care proposals, it is not meaningful at this time to predict the effect on the Company if any of these proposals is enacted.

Approximately 80% of home oxygen patients are covered by Medicare and other government programs. Federal law has altered the payment rates available to providers

Table of Contents

of Medicare services in various ways during the last several years. In November of 2003, Congress enacted the Medicare Improvement and Modernization Act, which will cause changes and reductions in home oxygen reimbursement over the next several years. These changes in reimbursement will cause increased downward pressure on the average selling price of the Company's products.

Protection of Intellectual Property Rights

The Company pursues a policy of protecting its intellectual property rights through a combination of patents, trademarks, trade secret laws, and confidentiality agreements. The Company considers the protection of its proprietary rights and the patentability of its products to be significant to the success of the Company. To the extent that the products to be marketed by the Company do not receive patent protection, competitors may be able to manufacture and market substantially similar products. Such competition or claims that the Company's products infringe the patent or trademark rights of others could have an adverse impact upon the Company's business.

Product Liability

The nature of the Company's business subjects it to potential legal actions asserting that the Company is liable for damages for product liability claims. Although the Company maintains product liability insurance in an amount which it believes to be customary in the industry, there is no assurance that this insurance will be sufficient to cover the cost of defense or judgments which might be entered against the Company. The type and frequency of these claims could have an adverse impact on the Company's results of operations and financial position.

Accounting Standards

Accounting standards promulgated by the Financial Accounting Standards Board change periodically. Changes in such standards may have an impact on the Company's future financial position.

In November 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 151 (Inventory Costs), an amendment of ARB No. 43, Chapter 4. The statement clarifies accounting for abnormal amounts of the idle facility expense, freight, handling costs, and spoilage and requires those items to be expensed when incurred. SFAS 151 is applicable to inventory costs incurred during fiscal years beginning after June 15, 2005. The Company adopted SFAS No. 151 on April 1, 2006, and the Company did not incur a significant impact to its financial statements.

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 123R (Share-Based Payment). SFAS 123R requires the Company to recognize compensation expense based on the fair value of equity instruments awarded to employees. The Company adopted SFAS 123R on April 1, 2006, and the Company did not incur a significant impact to its financial statements.

In June 2006, the Financial Accounting Standards Board ratified EITF Issue No. 06-3, How Taxes Collected from Customers and Remitted to Governmental Authorities

Table of Contents

Should be Presented in the Income Statement. The EITF provides guidance on the proper presentation of tax assessed by a governmental authority that is directly imposed on a revenue-producing transaction between a seller and a customer and requires disclosure of the Company's accounting policy decision. The consensus becomes effective for periods beginning after December 15, 2006. The Company is evaluating the impact of this interpretation and does not anticipate a significant impact to its financial statements upon implementation.

In June 2006, the Financial Accounting Standards Board issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes. Interpretation No. 48 prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. This Interpretation is effective for fiscal years beginning after December 15, 2006. The Company is evaluating the impact of this interpretation and does not anticipate a significant impact to its financial statements upon implementation.

Table of Contents

Additional Risk Factors

Additional factors, which might affect the Company's performance, may be listed from time to time in the reports filed by the Company with the Securities and Exchange Commission.

Item 3. Quantitative and Qualitative Disclosures about Market Risks

The Company has no significant exposure to market risk sensitive instruments or contracts.

Item 4. Controls and Procedures

The Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2006 (the Evaluation Date). Such evaluation was conducted under the supervision and with the participation of the Company's Chief Executive Officer (CEO) and its Chief Financial Officer (CFO). Based upon such evaluation, the Company's CEO and CFO have concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective to ensure that the Company record, process, summarize, and report information required to be disclosed by the Company in its quarterly reports filed under Securities Exchange Act within the time periods specified by the Securities and Exchange Commission's rules and forms. There have been no significant changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Part II
Other Information

Item 1. Legal Proceedings

None.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Submission of Matters to a Vote of Security Holders

None.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

- (a) 31.1 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CEO
- (b) 31.2 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CFO
- (c) 32* Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002
- (d) 99.1 Press release dated August 11, 2006

* The information in Exhibit 32 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this quarterly report), unless CHAD Therapeutics specifically incorporates the foregoing information into those documents by reference.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAD THERAPEUTICS, Inc.
(Registrant)

Date 08/14/2006

/s/ Earl L. Yager
Earl L. Yager
President and Chief Executive Officer

Date 08/14/2006

/s/ Tracy A. Kern
Tracy A. Kern
Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

Exhibit No.	Description of Exhibits
31.1	Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CEO
31.2	Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CFO
32*	Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002
99.1	Press release dated August 11, 2006

* The information in Exhibit 32 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this quarterly report), unless CHAD Therapeutics specifically incorporates the foregoing information into those documents by reference.